SAN DIEGO--(BUSINESS WIRE)--Jan 11, 2021--
DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2020 to meet or exceed $567 million, an increase of 23% over the fourth quarter of
"2021 is shaping up to be an exciting year for Dexcom and we look forward to updating you on our continued progress."
